EP. 1: Factors for Consideration When Choosing a Treatment for Patients With CLL
Mazyar Shadman, MD, MPH, explains the current standard-of-care treatment for patients with chronic lymphocytic leukemia and details the factors he considers when choosing an appropriate therapy.
EP. 2: The Current Treatment Landscape in CLL With the Advent of Novel Therapy Agents
Dr Mazyar Shadman reviews emerging targeted therapies shaping the treatment landscape and optimal sequencing in CLL.
EP. 3: BTK Inhibitor Investigations in the Frontline Treatment of CLL: Updates from ASH 2023
An overview of highlights from ASH 2023 on integrating BTK inhibitors into frontline CLL therapy.
EP. 4: Emergent Data from the ALPINE Trial Investigating Zanubrutinib in the Treatment of Relapsed/Refractory CLL
Dr Shadman provides an overview of zanubrutinib efficacy and safety data for relapsed/refractory CLL from the Phase 2 ALPINE trial.
EP. 5: The Evolving Treatment Landscape in Relapsed/Refractory CLL
Expert perspective on evolving data and strategies for managing relapsed/refractory CLL.
EP. 6: Improving Outcomes in CLL with BTK Inhibitors: Navigating Adverse Events, Sustaining Treatment, and Future Outlook in Relapsed/Refractory Disease
Dr Shadman provides insightful discussion on optimizing outcomes with BTK inhibition in CLL through adverse event mitigation and sustaining treatment in later lines.
2 Commerce Drive Cranbury, NJ 08512